Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

• Published in: Blood Vol. 121; no. 3; pp. 423 - 430
• Main Authors: Richter, Joshua, Neparidze, Natalia, Zhang, Lin, Nair, Shiny, Monesmith, Tamara, Sundaram, Ranjini, Miesowicz, Fred, Dhodapkar, Kavita M., Dhodapkar, Madhav V.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 17.01.2013; American Society of Hematology
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Combined Modality Therapy; Dendritic Cells - cytology; Dendritic Cells - immunology; Dendritic Cells - transplantation; Drug Synergism; Female; Galactosylceramides - metabolism; Galactosylceramides - therapeutic use; Humans; Killer Cells, Natural - drug effects; Killer Cells, Natural - immunology; Lenalidomide; Lymphocyte Activation - drug effects; Lymphocyte Activation - immunology; Male; Middle Aged; Monocytes - cytology; Multiple Myeloma - drug therapy; Multiple Myeloma - immunology; Plenary Paper; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use; Treatment Outcome

Natural killer T (iNKT) cells can help mediate immune surveillance against tumors in mice. Prior studies targeting human iNKT cells were limited to therapy of advanced cancer and led to only modest activation of innate immunity. Clinical myeloma is preceded by an asymptomatic precursor phase. Lenali...